Fludarabine-induced_JJ
immunosuppression_NN
is_VBZ
associated_VBN
with_IN
inhibition_NN
of_IN
STAT1_NN
signaling_NN
._.

Fludarabine_NN
is_VBZ
a_DT
nucleoside_JJ
analog_NN
used_VBN
in_IN
the_DT
treatment_NN
of_IN
hematologic_JJ
malignancies_NNS
that_WDT
can_MD
induce_VB
severe_JJ
and_CC
prolonged_JJ
immunosuppression_NN
._.

Although_IN
it_PRP
can_MD
be_VB
incorporated_VBN
into_IN
the_DT
DNA_NN
of_IN
dividing_VBG
cells_NNS
,_,
fludarabine_NN
is_VBZ
also_RB
a_DT
potent_JJ
inhibitor_NN
of_IN
cells_NNS
with_IN
a_DT
low_JJ
growth_NN
fraction_NN
,_,
thus_RB
it_PRP
must_MD
have_VB
other_JJ
mechanisms_NNS
of_IN
action_NN
._.

STAT1_NN
,_,
which_WDT
is_VBZ
activated_VBN
in_IN
response_NN
to_TO
many_JJ
lymphocyte-activating_JJ
cytokines_NNS
including_VBG
the_DT
interferons_NNS
,_,
is_VBZ
essential_JJ
for_IN
cell-mediated_JJ
immunity_NN
,_,
as_IN
the_DT
absence_NN
of_IN
this_DT
protein_NN
is_VBZ
associated_VBN
with_IN
prominent_JJ
defects_NNS
in_IN
the_DT
ability_NN
to_TO
control_VB
viral_JJ
infections_NNS
._.

Here_RB
we_PRP
show_VBP
that_IN
fludarabine_NN
,_,
but_CC
not_RB
the_DT
immunosuppressant_JJ
cyclosporine_NN
A_NN
,_,
inhibits_VBZ
the_DT
cytokine-induced_JJ
activation_NN
of_IN
STAT1_NN
and_CC
STAT1-dependent_JJ
gene_NN
transcription_NN
in_IN
normal_JJ
resting_VBG
or_CC
activated_VBN
lymphocytes_NNS
._.

Fludarabine_NN
caused_VBD
a_DT
specific_JJ
depletion_NN
of_IN
STAT1_NN
protein_NN
-LRB-_-LRB-
and_CC
mRNA_NN
-RRB-_-RRB-
but_CC
not_RB
of_IN
other_JJ
STATs_NNS
._.

This_DT
loss_NN
of_IN
STAT1_NN
was_VBD
also_RB
seen_VBN
in_IN
cells_NNS
from_IN
patients_NNS
treated_VBN
with_IN
fludarabine_NN
in_FW
vivo_FW
._.

Brief_JJ
exposure_NN
to_TO
fludarabine_NN
led_VBD
to_TO
a_DT
sustained_JJ
loss_NN
of_IN
STAT1_NN
,_,
analogous_JJ
to_TO
the_DT
prolonged_JJ
period_NN
of_IN
immunosuppression_NN
induced_VBN
by_IN
exposure_NN
to_TO
the_DT
drug_NN
in_FW
vivo_FW
._.

Thus_RB
,_,
STAT1_NN
may_MD
be_VB
a_DT
useful_JJ
target_NN
in_IN
the_DT
development_NN
of_IN
new_JJ
immunosuppressive_JJ
and_CC
antineoplastic_JJ
agents_NNS
._.

